$2.18
1.40%
Nasdaq, Sep 17, 02:56 pm EDT. Market open.
ISIN
CA98400H1029
Symbol
XBIT

XBiotech, Inc. Stock price

$2.15
-0.16 6.93% 1M
-0.15 6.52% 6M
-0.24 10.04% YTD
-0.54 20.07% 1Y
-2.30 51.69% 3Y
-13.51 86.27% 5Y
-9.86 82.10% 10Y
-18.40 89.54% 20Y
Nasdaq, Closing price Wed, Sep 16 2026
-0.05 2.05%
ISIN
CA98400H1029
Symbol
XBIT
Industry

Is XBiotech, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,134 stocks worldwide.

Key metrics

Basic
Market capitalization
$66.8m
Enterprise Value
$-42.8m
Net debt
positive
Cash
$109.5m
Shares outstanding
30.5m
Valuation (TTM | estimate)
P/E
negative
P/S
- | -
EV/Sales
- | -
EV/FCF
1.0
P/B
0.5
Dividends
DPS
$0.00
Yield 1Y | 5Y
0.0% | 0.0%
Growth 1Y | 5Y
- | -
Payout 1Y | 3Y
- | -
Increased
0 Years
Financials (TTM | estimate)
Revenue
$0.0 | -
EBITDA
$-46.8m
EBIT
$-48.2m
Net Income
$-45.1m
Free Cash Flow
$-40.8m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-34.5%
EBIT
-32.0%
Net Income
-57.5%
Free Cash Flow
-61.6%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
Financial Health
Equity Ratio
93.5%
Return on Equity
-
ROCE
-37.0%
ROIC
-210.8%
Debt/Equity
0.0
More
EPS
$-1.5
FCF per Share
$-1.3
Short interest
1.3%
Employees
87
Rev per Employee
-

XBiotech, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a XBiotech, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a XBiotech, Inc. forecast:

Buy
86%
Hold
14%

Financial data from XBiotech, Inc.

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 7.28 7.28
57% 57%
-
- Research and Development Expense 41 41
28% 28%
-
-47 -47
35% 35%
-
- Depreciation and Amortization 1.44 1.44
18% 18%
-
EBIT (Operating Income) EBIT -48 -48
32% 32%
-
Net Profit -45 -45
57% 57%
-

In millions USD.

Don't miss a Thing! We will send you all news about XBiotech, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

XBiotech, Inc. Stock News

Neutral
GlobeNewsWire
3 months ago
IND Application for V-SPINE Study Completes 30-Day FDA Review Without Clinical Hold, Clearing Path for U.S. Patient Enrollment

Company Profile

XBiotech, Inc. is a biopharmaceutical company. The firm engages in the development and commercialization of therapeutic antibodies. Its product pipeline includes oncology, infectious diseases, dermatology and inflammatory disorders. The company was founded by John Simard on March 22, 2005 and is headquartered in Austin, TX.

Head office Canada
CEO Dr. Shivaswamy
Employees 87
Founded 2005
Website www.xbiotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today